SG11201608835VA - Compounds for treating ophthalmic diseases and disorders - Google Patents
Compounds for treating ophthalmic diseases and disordersInfo
- Publication number
- SG11201608835VA SG11201608835VA SG11201608835VA SG11201608835VA SG11201608835VA SG 11201608835V A SG11201608835V A SG 11201608835VA SG 11201608835V A SG11201608835V A SG 11201608835VA SG 11201608835V A SG11201608835V A SG 11201608835VA SG 11201608835V A SG11201608835V A SG 11201608835VA
- Authority
- SG
- Singapore
- Prior art keywords
- disorders
- compounds
- ophthalmic diseases
- treating ophthalmic
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167490 | 2014-05-08 | ||
| EP14170616 | 2014-05-30 | ||
| PCT/EP2015/060166 WO2015169944A1 (en) | 2014-05-08 | 2015-05-08 | Compounds for treating ophthalmic diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608835VA true SG11201608835VA (en) | 2016-11-29 |
Family
ID=53051826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608835VA SG11201608835VA (en) | 2014-05-08 | 2015-05-08 | Compounds for treating ophthalmic diseases and disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11730716B2 (en) |
| EP (1) | EP3139914B1 (en) |
| JP (1) | JP6629840B2 (en) |
| KR (1) | KR102312186B1 (en) |
| CN (2) | CN116077665A (en) |
| AU (1) | AU2015257651B2 (en) |
| BR (1) | BR112016025997A8 (en) |
| CA (1) | CA2947067C (en) |
| CL (1) | CL2016002812A1 (en) |
| ES (1) | ES2960598T3 (en) |
| HK (1) | HK1231417A1 (en) |
| IL (1) | IL248732B (en) |
| MX (1) | MX2016014634A (en) |
| NZ (1) | NZ725574A (en) |
| PL (1) | PL3139914T3 (en) |
| SG (1) | SG11201608835VA (en) |
| WO (1) | WO2015169944A1 (en) |
| ZA (1) | ZA201607260B (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| EA035925B1 (en) | 2014-12-23 | 2020-09-01 | 4Д Фарма Рисерч Лимитед | Polypeptide and immune modulation |
| KR101942955B1 (en) | 2014-12-23 | 2019-01-28 | 4디 파마 리서치 리미티드 | Immune modulation |
| EP3307288B1 (en) | 2015-06-15 | 2019-07-24 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41060B1 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41010B1 (en) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| LT3240554T (en) | 2015-06-15 | 2019-11-11 | 4D Pharma Res Ltd | Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases |
| NZ777234A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| ES2662617T3 (en) | 2015-11-20 | 2018-04-09 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US20190025313A1 (en) * | 2015-12-30 | 2019-01-24 | Agios Pharmaceuticals, Inc. | Treatment of tumors incorporating mutant isocitrate dehydrogenase |
| CN108883139B (en) | 2016-03-04 | 2022-04-26 | 4D制药有限公司 | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TW201821093A (en) | 2016-07-13 | 2018-06-16 | 英商４Ｄ製藥有限公司 | Compositions comprising bacterial strains |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| CN110913878A (en) | 2017-05-22 | 2020-03-24 | 4D制药研究有限公司 | Compositions comprising bacterial strains |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| WO2018229189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| PT3638271T (en) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| DK3804737T3 (en) | 2017-06-14 | 2022-07-25 | 4D Pharma Res Ltd | COMPOSITIONS COMPRISING BACTERIAL STRAINS |
| CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| US20200121652A1 (en) * | 2017-06-16 | 2020-04-23 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
| WO2019164794A1 (en) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
| ES2972099T3 (en) * | 2018-03-09 | 2024-06-11 | Kiora Pharmaceuticals Gmbh | Ophthalmic formulation |
| RS65563B1 (en) * | 2018-03-16 | 2024-06-28 | Immunic Ag | Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| JP2021519334A (en) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ， インコーポレイテッド | Compositions and Methods for Inhibiting Dihydroorotoic Acid Dehydrogenase |
| WO2021189018A1 (en) | 2020-03-20 | 2021-09-23 | Clear Creek Bio, Inc. | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways |
| WO2021216548A1 (en) * | 2020-04-21 | 2021-10-28 | University Of Massachusetts | Methods and compositions for treatment of age-related macular degeneration |
| CN111638341A (en) * | 2020-07-01 | 2020-09-08 | 山东凯歌智能机器有限公司 | Kit and method for detecting PD-L1 gene mutation of peripheral blood circulating tumor cells of small cell lung cancer patients |
| KR20230116779A (en) * | 2020-10-15 | 2023-08-04 | 아슬란 파마슈티컬스 피티이 엘티디 | Treatment of autoimmune diseases with dihydroorotate hehydrogenase (DHODH) inhibitors |
| AU2022253683A1 (en) | 2021-04-09 | 2023-10-26 | Immunic Ag | Deuterated dhodh inhibitors |
| IL313501A (en) | 2021-12-23 | 2024-08-01 | Immunic Ag | Dhodh inhibitors containing a carboxylic acid bioisostere |
| US20230278979A1 (en) * | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
| AU2023230874A1 (en) * | 2022-03-09 | 2024-09-19 | Kiora Pharmaceuticals Gmbh | Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD297328A5 (en) | 1989-08-18 | 1992-01-09 | �������@���������k���Kk�� | 5-METHYL-ISOXALOL-4-CARBONSAEANEANILIDE AND 2 HYDROXYETHYLIDENE CYANO ACID ACIDANILIDES FOR THE TREATMENT OF EYE DISEASES |
| WO2004036182A2 (en) * | 2002-10-17 | 2004-04-29 | Control Delivery Systems, Inc. | Methods for monitoring treatment of disease |
| EP1581478A1 (en) * | 2002-12-23 | 2005-10-05 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| WO2004056746A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004056797A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| JP2006089485A (en) | 2004-08-24 | 2006-04-06 | Santen Pharmaceut Co Ltd | New heterocyclic amide derivative having dihydroorotate dehydrogenase inhibitory activity |
| WO2006022442A1 (en) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | Novel heterocyclic amide derivatives having dihydroorotate dehydrogenase inhibiting activity |
| WO2007038687A2 (en) | 2005-09-27 | 2007-04-05 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| ES2319596B1 (en) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF THE AMINO-NICOTINIC AND AMINO-ISONICOTINIC ACIDS. |
| UY31272A1 (en) | 2007-08-10 | 2009-01-30 | Almirall Lab | NEW DERIVATIVES OF AZABIFENILAMINOBENZOIC ACID |
| TWI530286B (en) * | 2009-05-04 | 2016-04-21 | 帕納特斯製藥格斯有限公司 | Anti-inflammatory agents as virostatic compounds |
| US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| US8686048B2 (en) * | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| AU2012304909B2 (en) * | 2011-06-10 | 2017-06-08 | Icon Bioscience, Inc. | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
| WO2015154820A1 (en) | 2014-04-11 | 2015-10-15 | Panoptes Pharma Gmbh | Anti-inflammatory agents as virostatic compounds |
-
2015
- 2015-05-08 MX MX2016014634A patent/MX2016014634A/en unknown
- 2015-05-08 PL PL15720340.7T patent/PL3139914T3/en unknown
- 2015-05-08 EP EP15720340.7A patent/EP3139914B1/en active Active
- 2015-05-08 JP JP2017510766A patent/JP6629840B2/en not_active Expired - Fee Related
- 2015-05-08 ES ES15720340T patent/ES2960598T3/en active Active
- 2015-05-08 CN CN202310101659.5A patent/CN116077665A/en active Pending
- 2015-05-08 CN CN201580036856.7A patent/CN106572968A/en active Pending
- 2015-05-08 WO PCT/EP2015/060166 patent/WO2015169944A1/en active Application Filing
- 2015-05-08 CA CA2947067A patent/CA2947067C/en active Active
- 2015-05-08 US US15/309,176 patent/US11730716B2/en active Active
- 2015-05-08 AU AU2015257651A patent/AU2015257651B2/en active Active
- 2015-05-08 NZ NZ725574A patent/NZ725574A/en unknown
- 2015-05-08 BR BR112016025997A patent/BR112016025997A8/en not_active Application Discontinuation
- 2015-05-08 SG SG11201608835VA patent/SG11201608835VA/en unknown
- 2015-05-08 KR KR1020167033322A patent/KR102312186B1/en active IP Right Grant
-
2016
- 2016-10-20 ZA ZA2016/07260A patent/ZA201607260B/en unknown
- 2016-11-03 IL IL248732A patent/IL248732B/en active IP Right Grant
- 2016-11-07 CL CL2016002812A patent/CL2016002812A1/en unknown
-
2017
- 2017-05-25 HK HK17105296.1A patent/HK1231417A1/en unknown
-
2023
- 2023-03-23 US US18/189,010 patent/US20230285355A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2960598T3 (en) | 2024-03-05 |
| PL3139914T3 (en) | 2023-11-27 |
| CN116077665A (en) | 2023-05-09 |
| BR112016025997A2 (en) | 2017-08-15 |
| JP2017514917A (en) | 2017-06-08 |
| EP3139914B1 (en) | 2023-07-26 |
| BR112016025997A8 (en) | 2021-07-06 |
| US11730716B2 (en) | 2023-08-22 |
| CN106572968A (en) | 2017-04-19 |
| CL2016002812A1 (en) | 2017-03-17 |
| US20170071904A1 (en) | 2017-03-16 |
| HK1231417A1 (en) | 2017-12-22 |
| MX2016014634A (en) | 2017-04-10 |
| NZ725574A (en) | 2022-08-26 |
| EP3139914A1 (en) | 2017-03-15 |
| AU2015257651B2 (en) | 2020-01-23 |
| US20230285355A1 (en) | 2023-09-14 |
| CA2947067C (en) | 2023-02-14 |
| WO2015169944A1 (en) | 2015-11-12 |
| ZA201607260B (en) | 2018-05-30 |
| KR102312186B1 (en) | 2021-10-14 |
| CA2947067A1 (en) | 2015-11-12 |
| IL248732B (en) | 2019-07-31 |
| IL248732A0 (en) | 2017-01-31 |
| EP3139914C0 (en) | 2023-07-26 |
| AU2015257651A1 (en) | 2016-11-10 |
| JP6629840B2 (en) | 2020-01-15 |
| KR20160147023A (en) | 2016-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1231417A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
| IL283561B (en) | Methods for treating ocular diseases | |
| HK1258588A1 (en) | Compounds and formulations for treating ophthalmic diseases | |
| HRP20190117T1 (en) | Mrna therapy for the treatment of ocular diseases | |
| HK1246179A1 (en) | Methods of treating retinal diseases | |
| IL249602A0 (en) | Methods and devices for treating posterior ocular disorders | |
| IL246791A0 (en) | Compositions and methods for treating ocular diseases | |
| GB201405232D0 (en) | Apparatus and methods for the treatment of ocular disorders | |
| HK1245127A1 (en) | Methods and compositions for treating brain diseases | |
| LT3210973T (en) | Heteroaryl compounds for the treatment of ophthalmic diseases | |
| HUE049600T2 (en) | Gls1 inhibitors for treating diseases | |
| HK1258994A1 (en) | Methods for treatment of diseases | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| HK1244782A1 (en) | Compositions and methods for treating diseases and conditions | |
| SG11201703330YA (en) | Iminosugars useful for the treatment of viral diseases | |
| EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
| PL3302463T3 (en) | Use of 3-deoxyanthocyanidins for treating ocular diseases | |
| GB201413532D0 (en) | Combination therapy for treating hearing disorders |